Drug-target residence time and its implications for lead optimization
The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index.
Abstract
Much of drug discovery today is predicated on the concept of selective targeting of particular bioactive macromolecules by low-molecular-mass drugs. The binding of drugs to their macromolecular targets is therefore seen as paramount for pharmacological activity. In vitro assessment of drug-target interactions is classically quantified in terms of binding parameters such as IC(50) or K(d). This article presents an alternative perspective on drug optimization in terms of drug-target binary complex residence time, as quantified by the dissociative half-life of the drug-target binary complex. We describe the potential advantages of long residence time in terms of duration of pharmacological effect and target selectivity.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The translation between slow inhibitor binding kinetics and sustained pharmacodynamic modulation has been studied for a numberoftarget classes (58).”
From Histone Deacetylase (HDAC) Inhibitor Kinetic Rate Constants Correlate with Cellular Histone Acetylation but Not Transcription and Cell Viability (2013) · cites this paper as [58]
In the citing paper
“Furthermore, the targets of infectious diseases usually have high replication rates, while covalent inhibitors tend to have long residence times making them less effective in this area [128].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [128]
In the citing paper
“Furthermore, longer residence times of drugs with their targets, as a result of slower off-rates, is a useful mechanism to extend in-vivo efficacy (59–61).”
From A PKA-selective inhibitor captures an open but more ordered conformation of the PKA catalytic subunit (2026) · cites this paper as [59]
Citations
Cites
Catalysis in chemistry and enzymology
Jencks, W. P. (1969) · Medical Entomology and Zoology · Cited by 3,217
Structure and Mechanism in Protein Science
Fersht, A. (1998) · Cited by 1,882
A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)
Wood, E. R., Truesdale, A. T., McDonald, O. B., Yuan, D., Hassell, A., Dickerson, S. H., Ellis, B., Pennisi, C., Horne, E., Lackey, K., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1168 · Cited by 1,122
Copeland, R. A. (2005) · PubMed · Cited by 1,092
Self-citationLiang, J., Woodward, C., & Edelsbrunner, H. (1998) · Protein Science · doi:10.1002/pro.5560070905 · Cited by 1,057
Enzymes: a practical introduction to structure, mechanism, and data analysis
(2001) · Choice Reviews Online · doi:10.5860/choice.38-3881 · Cited by 1,056
Optical biosensors in drug discovery
Cooper, M. A. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd838 · Cited by 1,015
Oppenheimer, N. J., & James, T. L. (1989) · Academic Press eBooks · Cited by 820
Rusnak, D. W., Lackey, K. E., Affleck, K., Wood, E. R., Alligood, K. J., Rhodes, N., Keith, B. R., Murray, D. M., Knight, W. B., Mullin, R. J., et al. (2001) · PubMed · Cited by 728
Enzymes: A Practical Introduction to Structure, Mechanism, and Data Analysis
Copeland, R. A. (2000) · Wiley eBooks · doi:10.1002/0471220639 · Cited by 726
Self-citation
Cited by
Items 501–600 of 1,003
Correlating Drug–Target Residence Time and Post-antibiotic Effect: Insight into Target Vulnerability
Davoodi, S., Daryaee, F., Chang, A. T., Walker, S. G., & Tonge, P. J. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00484 · Cited by 35
Ahn, S.-H., Jagger, B. R., & Amaro, R. E. (2020) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.9b00968 · Cited by 34
Covalent Inhibition of Bacterial Urease by Bifunctional Catechol-Based Phosphonates and Phosphinates
Pagoni, A., Grabowiecka, A., Tabor, W., Mucha, A., Vassiliou, S., & Berlicki, Ł. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01143 · Cited by 34
Hoare, S. R. J. (2021) · SLAS DISCOVERY · doi:10.1177/24725552211019653 · Cited by 34
Zhang, H., Yan, W., Sun, Y., Yuan, H., Su, L., Cao, X., Wang, P., Xu, Z., Hu, Y., Wang, Z., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00011 · Cited by 35
Development of the First Covalent Monopolar Spindle Kinase 1 (MPS1/TTK) Inhibitor
Serafim, R. A. M., Santiago, A. D. S., Schwalm, M. P., Hu, Z., dos Reis, C. V., Takarada, J. E., Mezzomo, P., Massirer, K. B., Kudolo, M., Gerstenecker, S., et al. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01165 · Cited by 36
Unzue, A., Dong, J., Lafleur, K., Zhao, H., Frugier, E., Caflisch, A., & Nevado, C. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm5009242 · Cited by 34
In Vivo Efficacy of Natural Product‐Inspired Irreversible Kinase Inhibitors
Barluenga, S., Jogireddy, R., Koripelly, G. K., & Winssinger, N. (2010) · ChemBioChem · doi:10.1002/cbic.201000205 · Cited by 36
Packeu, A., Wennerberg, M., Balendran, A., & Vauquelin, G. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00931.x · Cited by 35
Itoh, Y., Aihara, K., Mellini, P., Tojo, T., Ota, Y., Tsumoto, H., Solomon, V. R., Zhan, P., SUZUKI, M. T., Ogasawara, D., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01323 · Cited by 36
Non-competitive cyclic peptides for targeting enzyme–substrate complexes
McAllister, T. E., Yeh, T., Abboud, M. I., Leung, I. K. H., Hookway, E. S., King, O. N. F., Bhushan, B., Williams, S. T., Hopkinson, R. J., Münzel, M., et al. (2018) · Chemical Science · doi:10.1039/c8sc00286j · Cited by 34
Wang, S., Zhang, M., Liang, D., Sun, W., Zhang, C., Jiang, M., Liu, J., Li, J., Li, C., Xiao-hong, Y., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.04.047 · Cited by 35
Structure-kinetics relationships of Capadenoson derivatives as adenosine A 1 receptor agonists
Louvel, J., Guo, D. M., Soethoudt, M., Mocking, T. A. M., Lenselink, E. B., Mulder‐Krieger, T., Heitman, L. H., & IJzerman, A. P. (2015) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2015.07.023 · Cited by 34
Bacterial Enoyl-Reductases: The Ever-Growing List of Fabs, Their Mechanisms and Inhibition
Hopf, F. S. M., Roth, C. D., de Souza, E. V., Galina, L., Czeczot, A. D. M., Machado, P., Basso, L. A., & Bizarro, C. V. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.891610 · Cited by 37
de Witte, W. E. A., Wong, Y. C., Nederpelt, I., Heitman, L. H., Danhof, M., van der Graaf, P. H., Gilissen, R., & de Lange, E. C. M. (2015) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2016.1100163 · Cited by 35
Measurement of Ligand–Target Residence Times by 1H Relaxation Dispersion NMR Spectroscopy
Moschen, T., Grutsch, S., Juen, M. A., Wunderlich, C. H., Kreutz, C., & Tollinger, M. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b01110 · Cited by 35
Characterization of Covalent-Reversible EGFR Inhibitors
Smith, S. P., Keul, M., Engel, J., Basu, D., Eppmann, S., & Rauh, D. (2017) · ACS Omega · doi:10.1021/acsomega.7b00157 · Cited by 35
Bumbak, F., Keen, A. C., Gunn, N., Gooley, P. R., Bathgate, R. A. D., & Scott, D. J. (2018) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2018.03.020 · Cited by 33
Rapid optimisation of fragments and hits to lead compounds from screening of crude reaction mixtures
Baker, L. M., Aimon, A., Murray, J. B., Surgenor, A. E., Matassova, N., Roughley, S. D., Collins, P. M., Krojer, T. J., von Delft, F., & Hubbard, R. E. (2020) · Communications Chemistry · doi:10.1038/s42004-020-00367-0 · Cited by 33
Hsp90 Inhibitors and Drugs from Fragment and Virtual Screening
Roughley, S. D., Wright, L. M., Brough, P. A., Massey, A. J., & Hubbard, R. E. (2011) · Topics in current chemistry · doi:10.1007/128_2011_181 · Cited by 37
Post, J. M., Alexander, S., Wang, Y., Vincelette, J., Vergona, R., Kent, L., Bryant, J. A., Sullivan, M. E., Dole, W. P., Morser, J., et al. (2008) · Thrombosis Research · doi:10.1016/j.thromres.2008.04.009 · Cited by 33
Advanced molecular dynamics simulation methods for kinase drug discovery.
Aci-Sèche, S., Ziada, S., Braka, A., Arora, R., & Bonnet, P. (2016) · Future Medicinal Chemistry · doi:10.4155/fmc.16.9 · Cited by 29
Slow-Binding Inhibition of Mycobacterium tuberculosis Shikimate Kinase by Manzamine Alkaloids
Simithy, J., Fuanta, R., Alturki, M. S., Hobrath, J. V., Wahba, A. E., Piña, I. C., Rath, J., Hamann, M. T., DeRuiter, J., Goodwin, D. C., et al. (2018) · Biochemistry · doi:10.1021/acs.biochem.8b00231 · Cited by 35
A knottin scaffold directs the CXC-chemokine–binding specificity of tick evasins
Lee, A., Déruaz, M., Lynch, C. J., Davies, G., Singh, K., Alenazi, Y., Eaton, J. R. O., Kawamura, A., Shaw, J. P., Proudfoot, A. E. I., et al. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra119.008817 · Cited by 35
Targeting the unactivated conformations of protein kinases for small molecule drug discovery
Alton, G., & Lunney, E. A. (2008) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.3.6.595 · Cited by 33
Heise, C. E., Sullivan, S. K., & Crowe, P. D. (2007) · SLAS DISCOVERY · doi:10.1177/1087057106297362 · Cited by 33
The Added Value of Assessing Ligand–Receptor Binding Kinetics in Drug Discovery
Guo, D. M., Heitman, L. H., & IJzerman, A. P. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00273 · Cited by 33
Hoffmann, C., Nuber, S., Zabel, U., Ziegler, N., Winkler, C., Hein, P., Berlot, C. H., Bünemann, M., & Lohse, M. J. (2012) · Molecular Pharmacology · doi:10.1124/mol.112.077578 · Cited by 36
Anisotropic Friction in a Ligand-Protein Complex
Cai, W., Jäger, M., Bullerjahn, J. T., Hugel, T., Wolf, S., & Balzer, B. N. (2023) · Nano Letters · doi:10.1021/acs.nanolett.2c04632 · Cited by 32
Rao, M. S., McDuffie, E., & Sachs, C. W. (2023) · Toxics · doi:10.3390/toxics11100875 · Cited by 35
Behm, D. J., McAtee, J. J., Dodson, J. W., Neeb, M. J., Fries, H. E., Evans, C. A., Hernandez, R. R., Hoffman, K. D., Harrison, S. M., Lai, J. M., et al. (2008) · British Journal of Pharmacology · doi:10.1038/bjp.2008.266 · Cited by 32
Orally Inhaled Dihydroergotamine: A Review
Tepper, S. J. (2013) · Headache The Journal of Head and Face Pain · doi:10.1111/head.12184 · Cited by 32
Estimation of Kinetic and Thermodynamic Ligand-Binding Parameters Using Computational Strategies
Deganutti, G., & Moro, S. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2016-0224 · Cited by 36
Meisel, J. E., & Chang, M. (2017) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2017.04.011 · Cited by 32
Engel, J., Smith, S. P., Lategahn, J., Tumbrink, H. L., Goebel, L., Becker, C., Hennes, E., Keul, M., Unger, A., Müller, H., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00515 · Cited by 36
Bosma, R., Witt, G., Vaas, L. A. I., Josimovic, I., Gribbon, P. M., Vischer, H. F., Gul, S., & Leurs, R. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00667 · Cited by 35
Surface plasmon resonance study of interaction between lactoferrin and naringin
Nunes, N. M., de Paula, H. M. C., Coelho, Y. L., da Silva, L. H. M., & Pires, A. C. D. S. (2019) · Food Chemistry · doi:10.1016/j.foodchem.2019.125022 · Cited by 32
Zhao, Y., Liu, Q., Du, J., Meng, Q., & Zhang, L. (2023) · Smart Molecules · doi:10.1002/smo.20230012 · Cited by 38
Lee, S., Wang, D., Seeliger, M. A., & Tiwary, P. (2024) · Journal of Chemical Theory and Computation · doi:10.1021/acs.jctc.4c00503 · Cited by 33
ETA-receptor antagonists or allosteric modulators?
Mey, J. G. R. D., Compeer, M. G., Lemkens, P., & Meens, M. J. P. M. T. (2011) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2011.02.018 · Cited by 31
Malany, S., Hernández, L. M., Smith, W. F., Crowe, P. D., & Hoare, S. R. J. (2009) · Journal of Receptors and Signal Transduction · doi:10.1080/10799890902721339 · Cited by 31
How wet should be the reaction coordinate for ligand unbinding?
Tiwary, P., & Berne, B. J. (2016) · The Journal of Chemical Physics · doi:10.1063/1.4959969 · Cited by 31
Rechlin, C., Scheer, F. M., Terwesten, F., Wulsdorf, T., Pol, E., Fridh, V., Toth, P. M., Diederich, W. E., Heine, A., & Klebe, G. (2017) · ACS Chemical Biology · doi:10.1021/acschembio.7b00062 · Cited by 36
Wentsch, H. K., Walter, N. M., Bührmann, M., Mayer‐Wrangowski, S. C., Rauh, D., Zaman, G. J. R., Willemsen‐Seegers, N., Buijsman, R. C., Henning, M., Dauch, D., et al. (2017) · Angewandte Chemie International Edition · doi:10.1002/anie.201701185 · Cited by 33
Singh, K., Davies, G., Alenazi, Y., Eaton, J. R. O., Kawamura, A., & Bhattacharya, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-04378-1 · Cited by 37
Zhang, F., Jing, W., Hunt, A., Yu, H. M., Yang, Y., Wang, S., Chen, H., & Tao, N. J. (2018) · ACS Nano · doi:10.1021/acsnano.8b00235 · Cited by 33
Covalent allosteric modulation: An emerging strategy for GPCRs drug discovery
Bian, Y., Jun, J. J., Cuyler, J., & Xie, X. (2020) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2020.112690 · Cited by 33
Tabuchi, Y., Yang, J., & Taki, M. (2021) · Chemical Communications · doi:10.1039/d0cc08109d · Cited by 31
Kenakin, T. (2024) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-00958-9 · Cited by 35
A combinatorial biophysical approach; FTSA and SPR for identifying small molecule ligands and PAINs
Redhead, M. A., Satchell, R., Morkūnaitė, V., Swift, D., Petrauskas, V., Golding, E., Onions, S. T., Matulis, D., & Unitt, J. F. (2015) · Analytical Biochemistry · doi:10.1016/j.ab.2015.03.013 · Cited by 31
Wittenberg, N. J., Wootla, B., Jordan, L. R., Đenić, A., Warrington, A. E., Oh, S., & Rodriguez, M. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.896199 · Cited by 36
Kinetic Properties of Carbohydrate–Lectin Interactions: FimH Antagonists
Scharenberg, M., Jiang, X., Pang, L., Navarra, G., Rabbani, S., Binder, F. P. C., Schwardt, O., & Ernst, B. (2013) · ChemMedChem · doi:10.1002/cmdc.201300349 · Cited by 31
Identification of Covalent Binding Sites Targeting Cysteines Based on Computational Approaches
Zhang, Y., Zhang, D., Tian, H.-Z., Jiao, Y., Shi, Z., Ran, T., Liu, H., Lü, S., Xu, A., Qiao, X., et al. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00302 · Cited by 35
Balevičius, Z., Talbot, J., Tamošaitis, L., Plikusienė, I., Stirkė, A., Mickiene, G., Balevičius, S., Paulauskas, A., & Ramanavičius, A. (2019) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2019.126770 · Cited by 31
Soethoudt, M., Hoorens, M. W. H., Doelman, W., Martella, A., van der Stelt, M., & Heitman, L. H. (2018) · Biochemical Pharmacology · doi:10.1016/j.bcp.2018.03.018 · Cited by 31
Gómez‐Soler, M., Gehring, M. P., Lechtenberg, B. C., Zapata-Mercado, E. A., Ruelos, A., Matsumoto, M. W., Hristova, K. A., & Pasquale, E. B. (2022) · iScience · doi:10.1016/j.isci.2022.103870 · Cited by 30
Liu, H., Su, M., Lin, H., Wang, R., & Li, Y. (2022) · ACS Omega · doi:10.1021/acsomega.2c02156 · Cited by 36
Kamtekar, N., Pandey, A. D., Agrawal, N., Pissurlenkar, R. R. S., Borana, M. S., & Ahmad, B. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053499 · Cited by 32
Vauquelin, G. (2013) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-013-0881-0 · Cited by 32
Thomas, K., Haapalainen, A. M., Burgos, E. S., Evans, G. B., Tyler, P. C., Gulab, S. A., Guan, R. J., & Schramm, V. L. (2012) · Biochemistry · doi:10.1021/bi3009938 · Cited by 30
Xia, L., Burger, W. A. C., van Veldhoven, J. P. D., Kuiper, B. J., van Duijl, T. T., Lenselink, E. B., Paasman, E., Heitman, L. H., & IJzerman, A. P. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00950 · Cited by 30
Analysis of the adaptive multilevel splitting method on the isomerization of alanine dipeptide
Lopes, L. J. S., & Tony Lelièvre, A. (2019) · Journal of Computational Chemistry · doi:10.1002/jcc.25778 · Cited by 30
Li, S., Qin, C., Cui, S., Xu, H., Wu, F., Wang, J., Su, M., Fang, X., Li, D., Jiao, Q., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01491 · Cited by 30
Impact, determination and prediction of drug–receptor residence times for GPCRs
Tautermann, C. S. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.07.004 · Cited by 30
Ouyang, W., Ko, S. H., Wu, D., Wang, A. Y., Barone, P. W., Hancock, W. S., & Han, J. (2016) · Analytical Chemistry · doi:10.1021/acs.analchem.6b02517 · Cited by 29
Yang, G., Jin, Y., Wang, C., Zhang, J., Tang, Z., Peng, J., Liu, K., Li, Y., Zhou, Y., & Ma, X. (2016) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6b00235 · Cited by 29
Ai, Y., Hwang, L., MacKerell, A. D., Melnick, A. M., & Xue, F. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01686 · Cited by 30
Inhibitors of Immune Checkpoints: Small Molecule- and Peptide-Based Approaches
Fuchs, N. S., Zhang, L., Calvo‐Barreiro, L., Kuncewicz, K., & Gabr, M. T. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14010068 · Cited by 29
Bryant, J. A., Post, J. M., Alexander, S., Wang, Y., Kent, L., Schirm, S., Tseng, J., Subramanyam, B., Buckman, B. O., Islam, I., et al. (2008) · Thrombosis Research · doi:10.1016/j.thromres.2008.03.026 · Cited by 29
Mechanism and inhibition of the FabI enoyl-ACP reductase from Burkholderia pseudomallei
Liu, N., Cummings, J. E., England, K., Slayden, R. A., & Tonge, P. J. (2011) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkq509 · Cited by 29
Yang, X., Lin, Y., Heselpoth, R. D., Büyüktanır, Ö., Qin, J., Kung, F., Nelson, D. C., Leong, J. M., & Pal, U. (2015) · Cellular Microbiology · doi:10.1111/cmi.12487 · Cited by 29
Three stories on Eph kinase inhibitors: From in silico discovery to in vivo validation
Unzue, A., Lafleur, K., Zhao, H., Zhou, T., Dong, J., Kolb, P., Liebl, J., Zahler, S., Caflisch, A., & Nevado, C. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.01.057 · Cited by 29
Daryaee, F., Chang, A. T., Schiebel, J., Lü, Y., Zhang, Z., Kapilashrami, K., Walker, S. G., Kisker, C., Sotriffer, C., Fisher, S. L., et al. (2016) · Chemical Science · doi:10.1039/c6sc01000h · Cited by 31
Pathak, A. K., & Bandyopadhyay, T. (2015) · The Journal of Physical Chemistry B · doi:10.1021/acs.jpcb.5b08930 · Cited by 29
Liu, C., Liu, Z., & Wang, J. (2017) · PLoS ONE · doi:10.1371/journal.pone.0176208 · Cited by 29
de Witte, W. E. A., Vauquelin, G., van der Graaf, P. H., & de Lange, E. C. M. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.05.024 · Cited by 29
Molecular dynamics techniques for modeling G protein-coupled receptors
McRobb, F. M., Negri, A., Beuming, T., & Sherman, W. (2016) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2016.07.001 · Cited by 28
Chen, Q., Tan, H., Yu, H., & Shi, W. F. (2018) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2018.03.003 · Cited by 35
Kato, J., Inoue, T., Yokoyama, M., & Kuroha, M. (2021) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2021.1958780 · Cited by 31
Srivastava, M., Mittal, L., Kumari, A., Agrahari, A. K., Singh, M., Mathur, R., & Asthana, S. (2022) · Protein Science · doi:10.1002/pro.4398 · Cited by 30
Todsaporn, D., Zubenko, A. A., Kartsev, V. G., Aiebchun, T., Mahalapbutr, P., Petrou, A., Geronikaki, A. A., Диваева, Л. Н., Chekrisheva, V., Yıldız, İ., et al. (2023) · Molecules · doi:10.3390/molecules28073014 · Cited by 28
Tang, R., Wang, Z., Xiang, S., Wang, L., Yu, Y., Wang, Q., Deng, Q., Hou, T., & Sun, H. (2023) · JACS Au · doi:10.1021/jacsau.3c00195 · Cited by 30
Guo, D. M., Venhorst, S. N., Massink, A., van Veldhoven, J. P. D., Vauquelin, G., IJzerman, A. P., & Heitman, L. H. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12836 · Cited by 28
Thermodynamic and kinetic specificities of ligand binding
Yan, Z., Zheng, X., Wang, E., & Wang, J. (2013) · Chemical Science · doi:10.1039/c3sc50478f · Cited by 30
Gunnarsson, A., Mellby, L. D., Wallin, P., Svedhem, S., Jönsson, P., Wingren, C., & Höök, F. (2011) · Journal of the American Chemical Society · doi:10.1021/ja2047039 · Cited by 28
Zheng, X., & Wang, J. (2015) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1004212 · Cited by 29
Qu, S., Huang, S., Pan, X., Li, Y., & Hu, M. Y. (2016) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.6b00326 · Cited by 28
Trani, J. M. D., Moitessier, N., & Mittermaier, A. (2018) · Analytical Chemistry · doi:10.1021/acs.analchem.8b00993 · Cited by 28
Impact of plasma-protein binding on receptor occupancy: An analytical description
Peletier, L. A., Benson, N., & van der Graaf, P. H. (2008) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2008.09.014 · Cited by 28
Fatty Acid Biosynthesis and Oxidation
Zhang, H., Machutta, C. A., & Tonge, P. J. (2010) · Elsevier eBooks · doi:10.1016/b978-008045382-8.00668-7 · Cited by 33
A structure–kinetic relationship study using matched molecular pair analysis
Schuetz, D. A., Richter, L., Martini, R., & Ecker, G. F. (2020) · RSC Medicinal Chemistry · doi:10.1039/d0md00178c · Cited by 27
The prediction of protein–ligand unbinding for modern drug discovery
Zhang, Q., Zhao, N., Meng, X., Yu, F., Yao, X., & Liu, H. (2021) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2022.2002298 · Cited by 29
Zhou, J., Ji, M., Wang, X., Zhao, H., Cao, R., Jin, J., Li, Y., Chen, X., Li, S., Chen, X., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01522 · Cited by 27
Ojha, A. A., Srivastava, A., Votapka, L. W., & Amaro, R. E. (2023) · Journal of Chemical Information and Modeling · doi:10.1021/acs.jcim.2c01589 · Cited by 27
Behm, D., Aiyar, N., Olzinski, A., McAtee, J. J., Hilfiker, M., Dodson, J. W., Dowdell, S., Gz, W., Goodman, K., Sehon, C., et al. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.00889.x · Cited by 27
A Chemical Genetic Approach for Covalent Inhibition of Analogue-Sensitive Aurora Kinase
Koch, A., Rode, H. B., Richters, A., Rauh, D., & Hauf, S. (2012) · ACS Chemical Biology · doi:10.1021/cb200465c · Cited by 27
TSPO ligand residence time influences human glioblastoma multiforme cell death/life balance
Costa, B., Pozzo, E. D., Giacomelli, C., Taliani, S., Bendinelli, S., Barresi, E., Settimo, F. D., & Martini, C. (2014) · APOPTOSIS · doi:10.1007/s10495-014-1063-3 · Cited by 27
O’Hare, T., Eide, C. A., Agarwal, A., Adrian, L. T., Zabriskie, M. S., MacKenzie, R. J., LaTocha, D. H., Johnson, K. J., You, H., Luo, J., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3904 · Cited by 29
Antoine, T., Ott, D., Ebell, K., Hansen, K., Henry, L., Becker, F., & Hannus, S. (2016) · Analytical Biochemistry · doi:10.1016/j.ab.2016.02.017 · Cited by 30
Pharmacological property optimization for allosteric ligands: A medicinal chemistry perspective
Johnstone, S., & Albert, J. S. (2017) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2017.03.084 · Cited by 28
Metadata
- Authors
- Copeland, R. A., Pompliano, D. L., & Meek, T. D.
- Affiliations
- GlaxoSmithKline (United States) (US)
- Corresponding author
- Copeland, Robert A.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-08-04
- Volume
- 5
- Issue
- 9
- Pages
- 730-739
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2016408686
- Semantic Scholar
- 362824beb2008831aa65b4eb774e5c8703ff9c71
- Cited by
- 1,464
- References
- 46
- Citations by year
- 2026: 83 · 2025: 64 · 2024: 78 · 2023: 79 · 2022: 81 · 2021: 76 · 2020: 83 · 2019: 88 · 2018: 102 · 2017: 104 · 2016: 96 · 2015: 120 · 2014: 74 · 2013: 88 · 2012: 65
- FWCI
- 2.81
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Interaction Studies and Fluorescence Analysis
- Keywords
- drug-target residence time, lead optimization, drug selectivity, drug-target binding, binding affinity
- MeSH terms
- Binding, Competitive, Pharmaceutical Preparations, Humans, Kinetics, Ligands, Technology, Pharmaceutical, Drug Design, Drug Delivery Systems, Macromolecular Substances
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.